The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
Despite significant developments in the treatment of multiple myeloma (MM) over the past decade, many patients still experience relapse due to resistance to antimyeloma therapies. Particularly in the relapsed/refractory setting, recent treatment advances have resulted in significantly improved progn...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2023.17.123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327495651786752 |
|---|---|
| author | Adrian Schmidt |
| author_facet | Adrian Schmidt |
| author_sort | Adrian Schmidt |
| collection | DOAJ |
| description | Despite significant developments in the treatment of multiple myeloma (MM) over the past decade, many patients still experience relapse due to resistance to antimyeloma therapies. Particularly in the relapsed/refractory setting, recent treatment advances have resulted in significantly improved prognosis for MM patients. Among novel therapeutic modalities, B-cell maturation antigen (BCMA)-directed immunotherapies, including chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates (ADCs) and bispecific T cell engagers (BiTEs), have achieved remarkable clinical response in patients with relapsed/refractory MM (RRMM). This article discusses the recent progress in anti-BCMA targeted treatments for RRMM, with a focus on currently available agents.
PEER REVIEWED ARTICLE |
| format | Article |
| id | doaj-art-7122fbf4eb2847fab282e42373d59a71 |
| institution | Kabale University |
| issn | 2673-2092 2673-2106 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | THE HEALTHBOOK COMPANY LTD. |
| record_format | Article |
| series | healthbook TIMES. Oncology Hematology |
| spelling | doaj-art-7122fbf4eb2847fab282e42373d59a712025-08-20T03:47:52ZengTHE HEALTHBOOK COMPANY LTD.healthbook TIMES. Oncology Hematology2673-20922673-21062023-10-0117310.36000/hbT.OH.2023.17.123The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple MyelomaAdrian SchmidtDespite significant developments in the treatment of multiple myeloma (MM) over the past decade, many patients still experience relapse due to resistance to antimyeloma therapies. Particularly in the relapsed/refractory setting, recent treatment advances have resulted in significantly improved prognosis for MM patients. Among novel therapeutic modalities, B-cell maturation antigen (BCMA)-directed immunotherapies, including chimeric antigen receptor (CAR) T-cell therapy, antibody-drug conjugates (ADCs) and bispecific T cell engagers (BiTEs), have achieved remarkable clinical response in patients with relapsed/refractory MM (RRMM). This article discusses the recent progress in anti-BCMA targeted treatments for RRMM, with a focus on currently available agents. PEER REVIEWED ARTICLEhttps://doi.org/10.36000/hbT.OH.2023.17.123 |
| spellingShingle | Adrian Schmidt The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma healthbook TIMES. Oncology Hematology |
| title | The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma |
| title_full | The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma |
| title_fullStr | The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma |
| title_full_unstemmed | The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma |
| title_short | The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma |
| title_sort | gaining momentum of bcma directed therapies for relapsed refractory multiple myeloma |
| url | https://doi.org/10.36000/hbT.OH.2023.17.123 |
| work_keys_str_mv | AT adrianschmidt thegainingmomentumofbcmadirectedtherapiesforrelapsedrefractorymultiplemyeloma AT adrianschmidt gainingmomentumofbcmadirectedtherapiesforrelapsedrefractorymultiplemyeloma |